Results 221 to 230 of about 701,268 (244)
Some of the next articles are maybe not open access.
The Cancer Journal, 2009
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources
Progression-Free Survival: Meaningful or Simply Measurable?
Journal of Clinical Oncology, 2012The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of ...
Christopher M, Booth +1 more
openaire +2 more sources
The heterogeneity effect of surveillance intervals on progression free survival
Journal of Applied Statistics, 2022Progression-free survival (PFS) is an increasingly important surrogate endpoint in cancer clinical trials. However, the true time of progression is typically unknown if the evaluation of progression status is only scheduled at given surveillance intervals.
Zihang Zhong +6 more
openaire +2 more sources
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Journal of Clinical Oncology, 2007Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in
Marc, Buyse +8 more
openaire +2 more sources
Progression‐free survival 2: Is it ready for prime time?
Cancer, 2022Overall survival (OS) is considered the ideal end point for clinical trials in oncology, but the emergence of postprogression therapies and the need to accelerate therapeutic development necessitate the validation of surrogate end points for OS.
Ben George, Razelle Kurzrock
openaire +2 more sources
Progression/Recurrence-Free Survival 2 in Adjuvant Melanoma
NEJM Evidence, 2022The long-term outcome of patients with stage III melanoma - that is, melanoma that has spread to nearby lymph nodes, lymphatics, or skin - who have received treatment with immune checkpoint inhibitors is of substantial interest. The article by Eggermont et al.1 published in this issue of NEJM Evidence reports 5-year outcomes from the stage III melanoma
Ryan C, Augustin, Jason J, Luke
openaire +2 more sources
A statistical model for the dependence between progression‐free survival and overall survival
Statistics in Medicine, 2009AbstractAmong the surrogate endpoints for overall survival (OS) in oncology trials, progression‐free survival (PFS) is more and more taking the leading role. Although there have been some empirical investigations on the dependence structure between OS and PFS (in particular between the median OS and the median PFS), statistical models are almost non ...
Frank, Fleischer +2 more
openaire +2 more sources
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer
Anticancer Research, 2017Progression-free survival (PFS), which is evaluated in oncology clinical trials, is determined based on tumor progression evaluated according to an assessment schedule. There is possibly a bias in median PFS and hazard ratio (HR) for PFS depending on the assessment schedule referring to randomized controlled trials (RCTs) in patients with metastatic ...
Takanori, Tanase +3 more
openaire +2 more sources
A Hemorrhagic Clival Chordoma with a Long Progression-Free Survival
World Neurosurgery, 2017Chordomas and ecchordosis physaliphora may on rare occasions present with intracranial hemorrhage. Their distinction usually relies on the results of the Ki-67 proliferative index, with a result lower than 1% favoring ecchordosis physaliphora. Intracranial hemorrhagic chordomas have been linked to unfavorable prognosis, due to acute neurologic ...
Marcelo D, Vilela +2 more
openaire +2 more sources
Sensitivity analysis of progression‐free survival with dependent withdrawal
Statistics in Medicine, 2008AbstractWe develop a sensitivity analysis method for comparing treatment‐specific distributions where the endpoint is progression‐free survival (PFS). The censoring process may be informative due to selective patient withdrawal, which occurs whenever disease evaluation has been discontinued without progression being documented. The sensitivity analysis
Ping K, Ruan, Robert J, Gray
openaire +2 more sources